LOS ANGELES, June 3, 2013 — Eighty three percent of Americans say they do not always get a good night’s sleep on a regular basis, according to the 2013 Rx [...]]]> Anxiety, Mind Racing and Pain are Largest Culprits for the Sleep Deprived; Only 25 Percent Would Be Willing to Use Prescription Sleep Aid

LOS ANGELES, June 3, 2013 — Eighty three percent of Americans say they do not always get a good night’s sleep on a regular basis, according to the 2013 Rx Sleep Survey conducted by Harris Interactive on behalf of Targeted Medical Pharma, Inc. (OTCQB: TRGM), a Los Angeles-based biotechnology company. 

The results also revealed that while only 25 percent of Americans would be willing to take a prescription sleep aid to improve sleep quality, the  majority of Americans (71 percent) would rather use other means to get a good night’s rest. Slightly more than half of those Americans who said they would take a prescription sleep aid only would do so if the ingredients were recognized as safe as defined by the FDA.

“Most Americans who have trouble sleeping would rather not take prescription drugs because of the adverse side effects,” said Dr. Fred McCall-Perez, Ph.D., Vice President of Medical Affairs at Targeted Medical Pharma, who will be presenting the survey results in conjunction with clinical data comparing the medical food Sentra PM® and a commonly prescribed sleep drug  for the management of sleep disorders associated with depression, June 5 at SLEEP 2013 in Baltimore, MD (Abstract: 0663; Poster: 144). “Clinical data show our amino acid-based oral medication, Sentra PM improved the quality of sleep with no adverse side effects because it is formulated using ingredients that are Generally Recognized as Safe by the FDA.”

Click here or visit http://youtu.be/NfGHCBLhqrc to view a video of Dr. Fred McCall-Perez discussing sleep trends and prescription alternatives to pharmaceutical drugs.

Women Are More Affected

More women (88 percent) than men (78 percent) suffer from lack of sleep or sleep disorders, according to the survey, with 56 percent of women saying anxiety and stress are the leading reasons for lack of restful sleep, compared to only 40 percent of men. 

Forty-eight percent of Americans say stress and anxiety prevent them from getting a good night’s sleep on a regular basis. Other top reasons Americans do not always get a good night’s sleep include:

• Inability to turn off thoughts (47 percent): Women (51 percent);  Men (43 percent)
• Pain (38 percent): Women (40 percent); Men (35 percent)  
• Being overtired (32 percent): Women (36 percent); Men (28 percent)
• Background noise (23 percent): Women (27 percent); Men (20 percent)
• Children or pets (23 percent): Women (27 percent); Men (18 percent) 

Difficulty breathing (18 percent) and spouses or significant others (17 percent) rounded out the list of reasons Americans cited for not getting a good night’s sleep on a regular basis. 
The survey also found that people with household incomes of more than $100K annually (41 percent) were less inclined to say stress or anxiety were reasons for not getting good sleep, compared to those individuals with household incomes of less than $35K annually (55 percent). The same disparity went for pain.  Only 31 percent of America’s high earners said pain was a reason for not sleeping, compared to 45 percent of those making the lowest wages.

Despite differences between the two income groups, there were some similarities when it comes to reasons for not getting a good night’s sleep. The survey revealed that the inability to turn off thoughts and children or pets affected sleep the same regardless of income (48 percent and 24 percent, respectively).

The survey also discovered that 96 percent of the sleep-deprived are not taking prescription sleep aids to improve the quality of their slumber. More women (29 percent) than men (20 percent) would be willing to take a prescription sleep aid. The survey also found that women (68 percent) are less inclined than men (75 percent) to use other means than prescription sleep aids to help them sleep.

“It’s interesting to see the dichotomy between men and women when it comes to getting a good night’s sleep,” added Dr. McCall-Perez. “Women appear to be more stressed, more anxious, more tired, and more open than men to using a prescription sleep aid.”  

About the Rx Sleep Survey

The TRGM Sleep Survey was conducted by telephone within the United States by Harris Interactive between April 25-28, 2013 among 1,008 U.S. adults 18 years of age and older.  Results were weighted for age, sex, geographic region, and race when necessary to align them with their actual proportions in the population.

About Harris Interactive

Harris Interactive is one of the world’s leading custom market research firms. Known widely for the Harris Poll and for pioneering innovative research methodologies, Harris offers expertise in a wide range of industries including healthcare, technology, public affairs, energy, telecommunications, financial services, insurance, media, retail, restaurant, and consumer package goods. For more information, please visit www.harrisinteractive.com.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.  

# # #

The conference will be held on Thursday, May [...]]]> LOS ANGELES, May 22, 2013 — Targeted Medical Pharma, Inc. (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced that its Chief Executive and Chief Science Officer, Dr. William Shell, will be presenting at the Marcum MicroCap Conference.  

The conference will be held on Thursday, May 30, 2013 at the Grand Hyatt Hotel, located at 109 East  42nd Street in New York City.  Dr. Shell’s presentation will take place at 4:30 p.m. EST in the Estate 5 Biotech room. 
 
The event will host nearly 100 publicly traded companies with capitalizations under $500 million. The conference is estimating to draw more than 1,000 attendees including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. The conference will also feature panels on subjects highly relevant to small-cap corporate finance.

For full event details and registration information, please go to: www.marcumllp.com/microcap.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.  

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #

Los Angeles, May 15, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended [...]]]> – Company Reports Record Revenue through Continued Execution of Growth Plan –

Los Angeles, May 15, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended March 31, 2013. The Company posted record quarterly revenue of $2.811 million for the first quarter ended March 31, 2013, compared to revenue of $1.375 million for the first quarter ended March 31, 2012, an increase of 104.4 percent.

“I am thrilled to report the Company’s strongest recorded quarterly revenue as we continue to execute on our growth strategy,” commented William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma. “The expansion and application of current initiatives, and our ability to enter new markets, has resulted in increased revenue for all of our business lines, and helped us generate our fifth consecutive quarter of revenue growth. The actual growth in revenue was over one-hundred percent in the first quarter of 2013, compared to the first quarter of 2012, and we were cash flow positive from operations as well. I am optimistic about our growth and the team we have in place as we continue to strengthen our product pipeline and expand our sales and marketing efforts, while at the same time contain our operating expenses as we work to expand market share and enter new markets. I am also very encouraged with the expansion of our product line to support the needs of our customers.”

Financial Overview: 
Revenues for the three months ended March 31, 2013 were $2.811 million, compared to $1.375 million for the three months ended March 31, 2012, an increase of $1.436 million, or 104.4 percent. The increase in revenue was primarily attributed to a significant increase in prescriptions among workers compensation and commercial providers, along with improved collection rates for new and aged receivables.

Gross profit for the three months ended March 31, 2013 was $1.912 million, compared to $0.740 million for the three months ended March 31, 2012, an increase of $1.172 million, or 158.3 percent. The increase in gross profit was attributed to increased revenues resulting from a significant increase in collections and to a lesser extent payments associated with the Cambridge contract.

The net loss for the three months ended March 31, 2013 was $0.270 million and the diluted loss per share was $0.01, compared to a net loss of $0.976 million and diluted loss per share of $0.04 for the same period in 2012. The decrease in net loss was attributed to higher revenue combined with modest growth in operating expenses.

As of March 31, 2013 the Company had $34.6 million of unrecognized accounts receivables, not on the balance sheet due to our policy of not recognizing revenue for delivered product with a long collection cycle, until the cash is received. This unrecognized asset has the potential to become revenue in the future as the Company’s billing and collection subsidiary continues to collect accounts receivable on behalf of physicians using the Company’s managed business model and hybrid business model, for patient claims.

Adjusted EBITDA, a non-GAAP measure set forth in the table below, was negative $117 thousand for the three month period ended March 31, 2013, compared to negative $1.284 million for the three month period ended March 31, 2012, which is a reduction of $1.167 million or 91 percent.

“We’re very pleased to have generated positive cash flow from operations during the quarter,” said David Silver, M.D., President and Chief Operating Officer of Targeted Medical Pharma. “The results from the Cambridge agreement initiated in the first quarter of 2013, as well as our cost containment efforts, have established a good cash flow trajectory for the Company. We are focused on improving our margins and continue to leverage efficiencies in our distribution models, both of which contributed to a 68 percent operating loss improvement, as compared to the first quarter of 2012. We continue to build brand recognition in the medical community and are seeing increased demand from patients seeking our prescription medical foods. As we move forward with continued development of new products, we will remain focused on sustaining the growth reported for the first quarter.”

First Quarter Highlights:

• Expansion of private insurance market business
• Expansion of California Worker’s Compensation market business
• Issuance of our billing patent related to point of care medication dispensing and billing
• Submission of four new patent applications related to the oral stimulation of stem cells, particularly for the oral stimulation of progenitor red blood cell stem cells for treatment of chronic anemia
• Expansion of Agreement with Cambridge Medical Funding
• On April 19, 2013 the Company’s Registration Statement on Form S-1/A which registers up to 25,723,395 shares of common stock for resale was declared effective. The registration only involved existing shares and no new shares were issued. Of the 25,723,395 shares, 14,590,065 shares are owned by Company Insiders subject to Rule 144

Continued 2013 Strategic Initiatives:

• Expansion of sales and marketing efforts to increase prescribing in the Workers’ Compensation and private insurance markets
• Conduct additional clinical trials for current and pipeline products including Theramine®, and new formulas for red blood cell production and nasal decongestion.
• Continue development of new stem cell products for neuropathy, chronic anemia, and diabetes

Detailed financial data information is available on Targeted Medical Pharma’s annual report (Form 10-Q), which is accessible on the Company’s website at www.tmedpharma.com and on the SEC’s website at sec.gov/edgar.shtml.

About Targeted Medical Pharma, Inc. 
Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.

Reasons for Presentation of Non-GAAP Financial Measures
Statements made in this release include a non-GAAP financial measure. Such information is provided as additional information, not as an alternative to our consolidated financial statements presented in accordance with GAAP, and is intended to enhance an overall understanding of our current financial performance. We believe the non-GAAP financial measure provides useful information to management, investors and prospective investors by excluding certain charges and other amounts that we believe are not indicative of our core operating results. The non-GAAP measure is included to provide management, our investors and prospective investors with an alternative method for assessing our operating results in a manner that is focused on the performance of our ongoing operations and to provide a more consistent basis for comparison between quarters. The non-GAAP financial measure presented is Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, derivative revaluation, stock option compensation expense and stock issued for services). This term might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures reported by other companies. The financial statement tables that accompany this press release include reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure.

Forward Looking Statement 
This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Theramine® is a trademark of Targeted Medical Pharma Inc.

Click here to download press release.

# # #

Los Angeles, April 23, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced unaudited revenue of $2,811,000 for the first quarter ended on March 31, 2013, a 104% increase from the $1,375,000 [...]]]> –Company Reports Five Consecutive Quarters of Growth–

Los Angeles, April 23, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced unaudited revenue of $2,811,000 for the first quarter ended on March 31, 2013, a 104% increase from the $1,375,000 reported for the same period of the prior year and increased from $2,396,000 of the fourth quarter of 2012.

“We continued to experience steady growth of new markets nationally, and an increase in both prescribing and insurance reimbursements for our high value medications,” said Chief Executive and Chief Science Officer William Shell, M.D. “Our proprietary medical foods are becoming more widely prescribed as they are appealing to both physicians and patients who are in need of safe and efficacious medications for the treatment of complex disease states.”

2013 Strategic Initiatives

The key initiatives we intend to pursue to continue accelerating revenue growth for fiscal year 2013 are:

• Expand sales and marketing efforts to increase

-       prescribing in the Workers’ Compensation markets

-       prescribing in the private insurance markets

-       prescribing in the Medicare and Medicaid markets

• Conduct additional clinical trials for current and pipeline products
• Continue development of new products for neuropathy, chronic anemia, asthma, and diabetes

“This was our 5^th consecutive quarter of growth and our most exceptional to date,” said David S. Silver, M.D., Targeted Medical Pharma’s President and Chief Operating Officer. “The growing demand for our prescription medications by both patients and physicians who have long sought alternatives to more dangerous prescription drugs has helped support this sustained growth.”

Download the full release here.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #

–Company to Focus on Marketing/Sales; Expanding Product Pipeline in 2013–

Los Angeles, CA April 1, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today filed its 10-K and announced [...]]]>  

–Company to Focus on Marketing/Sales; Expanding Product Pipeline in 2013–

Los Angeles, CA April 1, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today filed its 10-K and announced the Company’s 2012 financial results.

“We are pleased to report that the second half of 2012 has come back strong and clearly reflects the traction we are seeing as we continue to gain momentum,” said Chief Executive and Chief Scientific Officer William Shell, M.D. “Revenue decreased in the first half of 2012 primarily due to concerns among physicians regarding the changes in legislation that could have impacted payments to physicians who dispense pharmaceuticals. Fortunately, the final bill did not impact the sale of medical foods or medical food convenience kits.  When physicians understood this in the second half of 2012, the Company saw an acceleration of growth.”

Dr. Shell continued, “A second bill passed accelerating payment of old workers compensation claims.  As our Company recognized revenue for workers compensation claims only upon collection, this benefits our Company twofold – both through improved cash flow and increased revenue.  In July, the acceleration of both dispenses and collections of workers compensation claims were seen due to the legislation that ultimately passed.  Another consequence of this legislation has been the near elimination of the compounded pain medication marketplace. The impact on the compounded medication marketplace, which is a competitor for medical foods in some cases, has also positively increased medical food dispensing and revenue, particularly the Company’s product Theramine^®.  The Company continues to show a narrowing of its net operating loss and improvement of its EBIDTA based on the preliminary unaudited analysis of its 2013 first quarter performance.”

As of December 31, 2012 the Company had a $34.4 million off balance sheet asset due to unrecorded accounts receivable for delivered products.  This unrecognized off balance sheet asset has the potential to be recorded as revenue in the future as the Company’s CCPI subsidiary collects receivables on behalf of the Company’s Physician Managed business model and Hybrid business model customers’ claims.

Dr. Shell, M.D. continued, “Our strategic focus over the past year has been to expand distribution channels and enhance reimbursement mix, increase cash collections, and further develop our pipeline of proprietary prescription-only medical foods. I am pleased to report that we have made solid progress against each of these initiatives, as the Company transitions from development stage into a growing business with excellent long-term potential.”

“On the corporate front, we welcomed Kerry Weems to our board of directors.  Mr. Weems is a nationally respected expert in health policy and government finance, who most recently was Acting Administrator of the Centers for Medicare and Medicaid Services (CMS) and Vice-Chairman of the American Health Information Community,” said Dr. Shell. “We also announced the appointment of Fred McCall-Perez, Ph.D. as our new director of medical affairs.

Key 2012 and Recent Achievements

• On March 4, 2013 the Company unveiled new results from an open label study of its oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The Company’s ESS system is designed to stimulate progenitor stem cells in the bone marrow.

• Awarded a patent on February 5, 2013 from the United States Patent and Trademark Office relating to a system and method for electronically submitting medication claims by point-of-care physicians. This is the seventh patent issued to the Company.

• In December of 2012, five of the Company’s core prescription-only medical foods were added to the U.S. Department of Veterans Affairs Federal Supply Schedule.

• Entered into an agreement with Cambridge Medical Funding Group, allowing physicians to assign California Workers’ Compensation receivables to Cambridge, providing revenue to the Company and physicians within seven to ten days of assignment for all products dispensed and billed for participating doctors.

• Reported data from an open-label pilot study indicating that Target Medical Pharma’s new amino acid-based oral product Percura™ reduced symptoms of pain and numbness related to peripheral neuropathy. This product is designed to orally stimulate progenitor neuronal stem cells, promoting their growth.

• Reported data indicating that Targeted Medical Pharma’s new amino acid oral formulation stimulated mature red blood cell and reticulocyte development. The study group included patients with chronic anemia. This product is designed to orally stimulate genesis of bone marrow progenitor stem cells. The company submitted four new patent applications related to the oral stimulation of progenitor stem cells.

• Confirmed a relationship between autonomic nervous system dysfunction and Gulf War Illness.  This is the first study to establish a medical basis for symptoms of Gulf War Illness in a large, representative sample of veterans using validated medical tests.

Published Scientific Papers

• Analyzing pharmacoeconomics of Targeted Medical Pharma’s drug, Theramine^®, versus non-steroidal anti-inflammatory drugs, showing a significant cost saving for patients taking Theramine compared to NSAIDs when accounting for the cost of the side effects of NSAIDs.

• Demonstrating that Sentra PM^® improved sleep latency and improved nighttime parasympathetic nervous system activity as a standalone medication or used in conjunction with a low dose of Trazadone, based on results from a clinical trial of the Company’s proprietary medical food product, Sentra PM.

Accepted to Present Clinical Posters

• Accepted to present “Theramine versus ibuprofen for the safe and effective management of chronic low back pain and inflammation,” at PAINWeek 2012, held in Las Vegas, Nevada, and at the 118^th Annual Meeting of AMSUS in Phoenix 2012.

2013 Corporate Objectives

The Company provided the following key strategic goals for 2013:

• Expanding its presence in the Workers’ Compensation marketplace, beginning with California and then nationally;
• Further increasing penetration in the private insurance market, as well as into Medicare and Medicaid populations; and accelerating its sales and marketing efforts.
• Continue developing its product pipeline.  The Company’s treatments for neuropathy, chronic anemia, asthma, nasal congestion and diabetes are currently undergoing clinical studies.

“We are dedicated to bringing our prescription medications to patients who have long sought alternatives to more dangerous prescription drugs,” said David S. Silver, M.D., Targeted Medical Pharma’s President and Chief Operating Officer.  “Increasing recognition of medical foods as a class within the U.S. Food & Drug Administration, along with heightened awareness among the medical community and patients, positions us for commercial success.  Ensuring broad patient access and building our brand presence represent key objectives, as we move forward in the current year.”

Detailed financial data information is available on Targeted Medical Pharma’s annual report (Form 10-K), which is accessible on the Company’s website and on this page of the SEC’s website.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.  The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Download Press Release Here.

#               #               #